Drug Development

Articles

Also, BASF opens lab in Mumbai; Evotek president and CEO to resign; more...

Company and People Notes: Hovione to Acquire Pfizer API site; Xceleron Appoints Michael Butler President and CEO; More...

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

At its annual business briefing held last week, Merck & Co. outlined its short- and long-term strategy for growth. Its strategy is focused on increased penetration in emerging markets, the establishment of a business for developing follow-on biologics or biosimilars, and a new commercial model for product life-cycle management.

Merck Forms Follow-On Biologics Business; Emphasizes Emerging Markets

Also, NicOx and DSM make manufacture and supply pact for naproxcinod drug substance; NovaRx appointed Norrie Russell president and COO; more...

Company and People Notes: BMS and AstraZeneca Expand Collaboration; Johnathan Knowles to Retire from Roche in 2009; More...

A Centers for Disease Control and Prevention (CDC) study confirmed that severe adverse reactions reported in the fall and winter of 2007 resulted from heparin contaminated with oversulfated chondroitin sulfate (OSCS).

CDC Identifies Cause of Heparin-Related Reactions

The Synthetic Chemical Organic Manufacturers Association (SOCMA) has raised concerns over requirements for security vulnerability assessments (SVA) under the US Department of Homeland Security's (DHS) Chemical Facility Anti-Terrorism Act Standards (CFATS).

SOCMA Cites Concern Over SVA Requirements for Chemical Facility Security Standards

Reps. John D. Dingell (D-MI), current chairman of the Committee on Energy and Commerce in the US House and Representatives, and Bart Stupak (D-MI), chairman of that committee?s Oversight and Investigations Subcommittee, said that moving the Food and Drug Administration Globalization Act and other measures for drug and food safety will be a key priority for the next Congress.

Lawmakers Pledge to Move on FDA Reform in the Next Congress

Also, AstraZeneca announces changes to its supply chain operations; Christian Velmer appointed head of Wyeth Canada; More...

Company and People Notes: Lilly Completes Acquisition of ImClone; Novocell CEO to Lead The Juvenile Diabetes Research Foundation; More...

A recent study shows life-science companies have difficulty in planning and executing change-management practices.

Change Management for Life Science Companies

2009 will likely be a difficult period for emerging biopharmaceutical companies.

Small-Cap Biotech Faces Financial Woes

The past year saw major acquisitions attempted, completed, rejected, and stalled.

Ingredients